

## CORRECTION

---

Muller DWM, Farivar RS, Jansz P, Bae R, Walters D, Clarke A, Grayburn PA, Stoler RC, Dahle G, Rein KA, Shaw M, Scalia GM, Guerrero M, Pearson P, Kapadia S, Gillinov M, Pichard A, Corso P, Popma J, Chuang M, Blanke P, Leipsic J, Sorajja P, on behalf of the Tendyne Global Feasibility Trial Investigators

### **Transcatheter Mitral Valve Replacement for Patients With Symptomatic Mitral Regurgitation: A Global Feasibility Trial**



**J Am Coll Cardiol 2017;69:381-91.**

On page 382, line 14 under the Methods heading,

“Exclusion criteria were: LV ejection fraction <30%, LV end-diastolic diameter >70 mm, severe mitral annular or leaflet calcification, left atrial or LV thrombus, prior mitral or aortic valve surgery, prior transcatheter mitral intervention, pulmonary artery systolic pressure  $\geq$ 70 mm Hg, severe tricuspid regurgitation, and severe right ventricular dysfunction with evidence of right heart failure.”

should have read:

“Exclusion criteria were: LV end-diastolic diameter >70 mm, severe mitral annular or leaflet calcification, left atrial or LV thrombus, prior mitral or aortic valve surgery, prior transcatheter mitral intervention, pulmonary artery systolic pressure  $\geq$ 70 mm Hg, severe tricuspid regurgitation, and severe right ventricular dysfunction with evidence of right heart failure. The data coordinating center excluded patients if the LVEF at the time of their qualifying transthoracic echo was <30%. However, 3 patients who were accepted as meeting all the inclusion criteria were subsequently found to have an EF <30% at the time of the intervention. These 3 patients were not disqualified.”

The authors apologize for this error.

The online version of the article has been corrected to reflect this change.

<http://dx.doi.org/10.1016/j.jacc.2017.01.020>